A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

ClinicalTrials.gov ID: NCT02436096

Public ClinicalTrials.gov record NCT02436096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Study identification

NCT ID: NCT02436096
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Enrollment: 519 participants

Conditions and interventions

Conditions

Interventions

TNX-102 SL Tablet, 2.8mg Drug
Placebo SL Tablet Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2015
Primary completion: Aug 31, 2016
Completion: Aug 31, 2016
Last update posted: Feb 6, 2025

2015 – 2016

United States locations

U.S. sites: 35
U.S. states: 20
U.S. cities: 34

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35216	—
Not listed	Phoenix	Arizona	85032	—
Not listed	Sacramento	California	95825	—
Not listed	San Diego	California	92103	—
Not listed	Brandon	Florida	33511	—
Not listed	DeLand	Florida	32720	—
Not listed	Lakeland	Florida	33805	—
Not listed	Ocala	Florida	34471	—
Not listed	Orlando	Florida	32806	—
Not listed	Tampa	Florida	33613	—
Not listed	Tampa	Florida	33614	—
Not listed	West Palm Beach	Florida	33409	—
Not listed	Columbus	Georgia	31904	—
Not listed	Smyrna	Georgia	30080	—
Not listed	Evansville	Indiana	47714	—
Not listed	North Dartmouth	Massachusetts	02747	—
Not listed	Ann Arbor	Michigan	48104	—
Not listed	Jackson	Mississippi	39202	—
Not listed	Williamsville	New York	14221	—
Not listed	Cincinnati	Ohio	45206	—
Not listed	Columbus	Ohio	43212	—
Not listed	Middleburg Heights	Ohio	44130	—
Not listed	Medford	Oregon	97504	—
Not listed	Portland	Oregon	97210	—
Not listed	Allentown	Pennsylvania	18104	—
Not listed	Warwick	Rhode Island	02888	—
Not listed	Greer	South Carolina	29650	—
Not listed	Mt. Pleasant	South Carolina	29464	—
Not listed	Dallas	Texas	75231	—
Not listed	Salt Lake City	Utah	84102	—
Not listed	Charlottesville	Virginia	22911	—
Not listed	Norfolk	Virginia	23507	—
Not listed	Bellevue	Washington	98007	—
Not listed	Seattle	Washington	98104	—
Not listed	Kenosha	Wisconsin	53142	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02436096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 6, 2025 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02436096 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →